SwePub
Sök i LIBRIS databas

  Utökad sökning

id:"swepub:oai:DiVA.org:oru-102833"
 

Sökning: id:"swepub:oai:DiVA.org:oru-102833" > Spasticity treatmen...

  • Smith, Kelsi A.Karolinska Institutet (författare)

Spasticity treatment patterns among people with multiple sclerosis : a Swedish cohort study

  • Artikel/kapitelEngelska2023

Förlag, utgivningsår, omfång ...

  • 2022-12-20
  • BMJ Publishing Group Ltd,2023
  • printrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:oru-102833
  • https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-102833URI
  • https://doi.org/10.1136/jnnp-2022-329886DOI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:151489400URI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • Funding agency:UK Economic and Social Research Council (ESRC) to the International Centre for Life Course Studies ES/R008930/1
  • BACKGROUND: Spasticity is common among people with multiple sclerosis (MS), but there are few studies of spasticity treatment patterns. We aim to describe associations with spasticity treatment measured primarily by oral baclofen use.METHODS: This cohort study using Swedish registers included 1826 and 3519 people with incident and prevalent MS (pwIMS, pwPMS) respectively, followed from 2005 to 2014. Cox regression assessed factors associated with new baclofen prescriptions and its discontinuation.RESULTS: A total of 10% of pwIMS and 19% of pwPMS received baclofen, a drug prescribed specifically for spasticity in Sweden, of which many patients had relapsing-remitting course. Prescriptions occurred soon after MS diagnosis: pwIMS received baclofen typically within 6 months of diagnosis, and pwPMS within 3 years. Younger patients compared with older patients were three times more likely to receive baclofen with similar disability level measured using Expanded Disability Severity Scores (EDSS). Patients aged 18-44 years with EDSS 3.0-5.0 have an HR for baclofen use of 5.62 (95% CI 2.91 to 10.85) and EDSS 6+ have an HR of 15.41 (95% CI 7.07 to 33.58) compared with individuals with EDSS 0-2.5. In comparison, patients aged 45+ years with EDSS 3.0-5.0 have an HR of 2.05 (95% CI 1.10 to 3.82) and EDSS 6+ a hour 4.26 (95% CI 1.96 to 9.17). Baclofen discontinuation was high: 49% (95% CI 0.42 to 0.57) of pwIMS discontinued within 150 days of dispensation, 90% discontinued within 2 years including patients with progressive course or higher EDSS. Associations among pwPMS and sensitivity analyses including additional treatments were similar.CONCLUSIONS: Younger patients with MS are more likely to receive baclofen compared with older patients with MS. High rates of baclofen discontinuation highlight the need for more tolerable and efficacious spasticity treatments and monitoring of spasticity among people with MS.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Piehl, FredrikClinical Neuroscience, Karolinska Institute, Stockholm, Sweden; Centre of Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden; Academic Specialist Centre, Centre of Neurology, SLSO, Stockholm, Sweden (författare)
  • Olsson, TomasKarolinska Institutet (författare)
  • Alfredsson, LarsKarolinska Institutet (författare)
  • Hillert, JanKarolinska Institutet (författare)
  • Kockum, IngridKarolinska Institutet (författare)
  • Strid, PernillaKarolinska Institutet (författare)
  • Montgomery, Scott,1961-Karolinska Institutet,Örebro universitet,Institutionen för medicinska vetenskaper,Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institute, Stockholm, Sweden; Clinical Epidemiology and Biostatistics, School of Medical Sciences, Faculty of Medicine and Health, Örebro University, Örebro, Sweden; Department of Epidemiology and Public Health, University College London, London, UK(Swepub:oru)smy (författare)
  • Karolinska InstitutetClinical Neuroscience, Karolinska Institute, Stockholm, Sweden; Centre of Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden; Academic Specialist Centre, Centre of Neurology, SLSO, Stockholm, Sweden (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Journal of Neurology, Neurosurgery and Psychiatry: BMJ Publishing Group Ltd94:5, s. 337-3480022-30501468-330X

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy